Bristol-Myers Squibb Co., of Princeton, N.J.; the University ofOxford; and Amersham International plc, of Buckinghamshire, U.K.,reached a licensing agreement regarding Ceretec, a brain imagingagent designed for use in the antemortem diagnosis of Alzheimer'sdisease. The agreement allows Amersham to file a supplemental newdrug application with the FDA, which is planned later this year. Theapplication will be based on data from Oxford University as part of aresearch alliance funded by Bristol-Myers Squibb. Research showedthe agent in combination with computed tomography tests detectedAlzheimer's with 90 percent accuracy and had a false positive rate ofless than 5 percent.
Matritech Inc., of Newton, Mass., said its NMP22 Test Kit fordetection of bladder cancer identified six of six patients who went onto develop the invasive form of the disease.
Metra Biosystems Inc., of Mountain View, Calif., registered to sell2.3 million shares in a public offering. The company developsdiagnostic products for detecting and managing metabolic bonediseases.
Molecular Biosystems Inc., of San Diego, and Mallinckrodt GroupInc., of St. Louis, completed patient enrollment in a Phase III studyof FS069, a next-generation ultrasound contrast agent.
(c) 1997 American Health Consultants. All rights reserved.